NOV 02, 2020 7:00 AM PST

New Cancer Drug Reboots Stalled Immunotherapies

WRITTEN BY: Tara Fernandez


In contrast to traditional chemotherapies, immunotherapies reprogram the patient’s own immune system to fight tumor cells. The hope is that these types of treatments will be more effective at permanently eliminating cancer cells and have fewer side effects due to their more targeted nature. However, clinical testing of immunotherapeutics has revealed that certain types of malignancies are resistant to immunotherapies.

Cancer researchers have developed a new drug to kickstart the immune system in patients with cancers that are unresponsive to immunotherapies. A study published in the Proceedings of the National Academy of Sciences details data from a clinical trial of plerixafor in patients with advanced pancreatic or colorectal cancer. The aim of the study was to evaluate the potential of the drug in enhancing the performance of a class of immunotherapies known as immune checkpoint inhibitors. Such treatments unleash the body’s immune system by lifting inbuilt safety nets, activating immune cells to aggressively target and remove tumors.

"Those tumors often do not seem to be visible to the immune system and do not seem to be unmasked by these therapies that are currently available,” explained Tobias Janowitz, a lead author of the study. “And we have reasons to believe that that is because they can engage an immune suppressive pathway that keeps most of the immune cells out of the cancer cell nest."

Analysis of the patient samples revealed that their tumors had been infiltrated by immune cells after receiving plerixafor — a critical first step required for effective immunotherapies. The team was encouraged by additional data that showed plerixafor was also able to help patients whose cancers do respond to checkpoint inhibitors, demonstrating its potential versatility in the clinic.

"I am delighted that the work of this multi-disciplinary team has translated important laboratory findings into patients, with the potential to make a difference in these hard-to-treat cancers," said Duncan Jodrell who led the clinical trial.

Sources: PNAS, Medical Xpress.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
JUL 27, 2020
Cell & Molecular Biology
White Blood Cells Are Essential to the Developing Brain
JUL 27, 2020
White Blood Cells Are Essential to the Developing Brain
The brain is protected by a protective shield called the blood-brain barrier, which only allows certain things to pass t ...
AUG 21, 2020
Microbiology
Vaccine Aimed at Fungi May Also Protect Against MRSA
AUG 21, 2020
Vaccine Aimed at Fungi May Also Protect Against MRSA
Staphylococcus aureus is a common bacterium. If it stays on the skin it's harmless, but if it gets into the bloodstream, ...
SEP 07, 2020
Immunology
CRISPR Pumps the Brakes on the Immune System to Support Gene Therapies
SEP 07, 2020
CRISPR Pumps the Brakes on the Immune System to Support Gene Therapies
The ability to edit the human genome using CRISPR has been heralded as a revolution in medicine. However, one of the big ...
SEP 11, 2020
Immunology
Could a Drug for Cats Treat COVID?
SEP 11, 2020
Could a Drug for Cats Treat COVID?
Canadian researchers have discovered that a drug used to treat coronavirus infections in cats shows promise in helping C ...
NOV 06, 2020
Immunology
The Coronavirus Is No Match Against Sybody 23
NOV 06, 2020
The Coronavirus Is No Match Against Sybody 23
The virus that causes COVID-19, SARS-CoV-2, uses its spike protein to gain access to cells, by binding to the ACE2 recep ...
NOV 16, 2020
Immunology
Measles Is Back and COVID Isn't Helping
NOV 16, 2020
Measles Is Back and COVID Isn't Helping
Measles is a highly contagious and airborne viral disease. There is no treatment besides supportive care once a person b ...
Loading Comments...